Aerovate Therapeutics, Inc. (AVTE)

NASDAQ: AVTE · IEX Real-Time Price · USD
18.03
-0.28 (-1.53%)
Dec 5, 2022 3:59 PM EST - Market closed
-1.53%
Market Cap 450.52M
Revenue (ttm) n/a
Net Income (ttm) -44.71M
Shares Out 24.45M
EPS (ttm) 28.96
PE Ratio 0.62
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 90,413
Open 17.91
Previous Close 18.31
Day's Range 17 - 18.33
52-Week Range 7.74 - 27.83
Beta n/a
Analysts Buy
Price Target 26.86 (+49.5%)
Earnings Date Nov 21, 2022

About AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. [Read more]

Industry Biotechnology
IPO Date Jun 30, 2021
Employees 33
Stock Exchange NASDAQ
Ticker Symbol AVTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AVTE stock is "Buy." The 12-month stock price forecast is 26.86, which is an increase of 49.47% from the latest price.

Price Target
$26.86
(49.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hy...

Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants Phase 1 results showed that AV-101 wa...

2 weeks ago - GlobeNewsWire

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives o...

3 weeks ago - GlobeNewsWire

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor Adaptive and efficient trial design may allow for expedited development timeline while...

1 month ago - GlobeNewsWire

GLSI, AVTE: The Top 5 Short Squeeze Stocks to Watch This Week

Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Squeeze Leaderboard.

Other symbols: GLSIBEATNERVVORB
1 month ago - InvestorPlace

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives o...

3 months ago - GlobeNewsWire

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Deve...

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH

6 months ago - GlobeNewsWire

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of...

6 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) --  Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

8 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hyperten...

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives o...

11 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives o...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.   (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option ...

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patien...

1 year ago - GlobeNewsWire

Drug Formulation Developer Aerovate Therapeutics Kick Starts Trading Today With Upsized Debut

Just shy of a full year after emerging from stealth mode, Aerovate Therapeutics Inc (NASDAQ: AVTE) is listing onto NASDAQ with an upsized offering. The company priced 8.68 million shares at $14, the mid...

1 year ago - Benzinga

Aerovate Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patien...

1 year ago - GlobeNewsWire